Fecal Microbiota Transplantation for Ulcerative Colitis

Launched by GUANGZHOU FIRST PEOPLE'S HOSPITAL · Jan 12, 2019

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called fecal microbiota transplantation (FMT) for people with ulcerative colitis, a condition that causes inflammation in the intestines. FMT involves taking a healthy donor's stool and using it to help restore the balance of good bacteria in the gut of a patient with ulcerative colitis. The goal of the trial is to determine how effective and safe this treatment is for patients suffering from moderate to severe cases of the disease.

To participate in this trial, individuals must be between 65 and 74 years old and have active, moderate to severe ulcerative colitis, as indicated by a specific scoring system. They should also have a history of using a certain medication called 5-ASA and be able to undergo an examination called endoscopy. However, those who have taken antibiotics recently, have certain severe health issues, or have a history of colon cancer are not eligible. Participants in the study can expect to receive this innovative treatment and will be monitored closely for safety and effectiveness throughout the trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Active, moderate to severe severity (Mayo score more than 6)
• • Safety using history of 5-ASA
• • Able to undergo endoscopy examination
• Exclusion Criteria:
• • Antibiotic using in 7 days
• • High risk of toxic megacolon
• • Colon cancer or neoplasia in pathophysiology
• • Other severe diseases (eg: cardiovascular, respiratory, gastroenteral and kidney diseases)